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The human IL22RA2 gene co-produces three protein isoforms in dendritic cells
[IL-22 binding protein isoform-1 (IL-22BPi1), IL-22BPi2, and IL-22BPi3]. Two of these,
IL-22BPi2 and IL-22BPi3, are capable of neutralizing the biological activity of IL-22. The
function of IL-22BPi1, which differs from IL-22BPi2 through an in-frame 32-amino acid
insertion provided by an alternatively spliced exon, remains unknown. Using transfected
human cell lines, we demonstrate that IL-22BPi1 is secreted detectably, but at much
lower levels than IL-22BPi2, and unlike IL-22BPi2 and IL-22BPi3, is largely retained in
the endoplasmic reticulum (ER). As opposed to IL-22BPi2 and IL-22BPi3, IL-22BPi1 is
incapable of neutralizing or binding to IL-22 measured in bioassay or assembly-induced
IL-22 co-folding assay. We performed interactome analysis to disclose the mechanism
underlying the poor secretion of IL-22BPi1 and identified GRP78, GRP94, GRP170, and
calnexin as main interactors. Structure-function analysis revealed that, like IL-22BPi2,
IL-22BPi1 binds to the substrate-binding domain of GRP78 as well as to the
middle domain of GRP94. Ectopic expression of wild-type GRP78 enhanced, and
ATPase-defective GRP94mutant decreased, secretion of both IL-22BPi1 and IL-22BPi2,
while neither of both affected IL-22BPi3 secretion. Thus, IL-22BPi1 and IL-22BPi2 are
bona fide clients of the ER chaperones GRP78 and GRP94. However, only IL-22BPi1
activates an unfolded protein response (UPR) resulting in increased protein levels of
GRP78 and GRP94. Cloning of the IL22RA2 alternatively spliced exon into an unrelated
cytokine, IL-2, bestowed similar characteristics on the resulting protein. We also found
that CD14++/CD16+ intermediate monocytes produced a higher level of IL22RA2
mRNA than classical and non-classical monocytes, but this difference disappeared in
immature dendritic cells (moDC) derived thereof. Upon silencing of IL22RA2 expression
in moDC, GRP78 levels were significantly reduced, suggesting that native IL22RA2
expression naturally contributes to upregulating GRP78 levels in these cells. The IL22RA2
Gómez-Fernández et al. Characterization of Human IL-22BP Isoforms
alternatively spliced exon was reported to be recruited through a single mutation in
the proto-splice site of a Long Terminal Repeat retrotransposon sequence in the ape
lineage. Our work suggests that positive selection of IL-22BPi1 was not driven by IL-22
antagonism as in the case of IL-22BPi2 and IL-22BPi3, but by capacity for induction of
an UPR response.
Keywords: IL-22BP, IL-22, GRP78, GRP94, UPR, isoform, dendritic cells, exonization
INTRODUCTION
Interleukin-22 (IL-22) is an IL-10-type cytokine produced by a
wide variety of immune cells including innate lymphoid cells,
CD4+ Th17 and Th22 cells (1, 2) and neutrophils (3). It is
crucially involved in diverse pathologic processes related to
autoimmunity, epithelial cell characteristics and transformation,
as well as to damage conferred by tumors. It is specifically
involved in regulating the immunity of barrier surfaces (4). IL-
22, which signals through a membrane receptor composed by the
heterodimer IL-22R1/IL-10R2, has the unique feature among the
IL-10 family cytokines of being recognized by a secreted receptor
called IL-22 binding protein (IL-22BP), which is coded for by the
IL22RA2 gene. IL22RA2 is expressed in different cells from the
myeloid lineage including dendritic cells from lymphoid and gut
tissues (5–7) and from skin (8), eosinophils in the gut mucosa
(9), as well as in lymphoid CD4+ T cells isolated from intestinal
tissue (10). Recently epidermal keratinocytes have been found to
be the major IL-22BP source in the skin in steady state conditions
(11). Specific to humans, this gene expresses three alternatively
spliced variants called IL22RA2v1 (IL-22BPi1), IL22RA2v2 (IL-
22BPi2), and IL22RA2v3 (IL-22BPi3), which are co-expressed
in moDCs (5, 12). The murine Il22ra2 gene produces only
one isoform, which is the homolog of human IL22RA2v2 (13).
Surface plasmon resonance (SPR) studies have been performed
to estimate affinity of interaction of human IL-22BPi2 with IL-22
(14, 15). These revealed that IL-22BPi2 neutralizes the biological
activity of IL-22 via formation of an exceptionally tight (Kd ≈ 1
pM) complex with IL-22 (15–18). Compared to a soluble form of
the cell surface receptor sIL-22R1, the dissociation half-time (t½)
values of the IL-22/IL-22BPi2 complex are strikingly larger (≈4.7
days for IL-22/IL-22BPi2 vs. 7min for IL-22/sIL-22R1). Thus,
IL-22BPi2 appears to exhibit a much higher affinity for IL-22
than the cell surface receptor (15). However, IL-22BPi3 displays
lower affinity for IL-22 with binding kinetics similar to the IL-
22/sIL-22R1 complex (15), and it is less efficient in blocking
IL-22 bioactivity (12). The biological function of IL-22BPi1 that
contains a 32-amino acid insertion within the reading frame
at position 67 of IL-22BPi2, coded for by alternatively spliced
exon-4, has not been reported, and is explored in this article.
The role of IL-22BP in disease is being elucidated, mainly
through analysis of IL-22BPi2 in mouse models. Mirroring IL-
22 biology, both protective and inflammatory roles have been
attributed to IL-22BPi2. In a mouse model of inflammation-
induced colon cancer, IL-22BPi2 produced by DC in the
colon exerted a protective role by controlling tumorigenesis
and epithelial cell proliferation (6). In contrast, IL-22BPi2
production is enhanced during inflammation in Crohn’s Disease
and ulcerative colitis and may exert pathogenic effects through
blockage of protective IL-22 (9, 10). IL-22BPi2-knockout
mice showed aggravation of psoriasis-induction with increased
expression of IL-22-associated anti-microbial peptides, and this
effect was reproduced following injection of a neutralizing
antibody for IL-22BPi2 (19). IL-22BPi2 expression has also been
detected in mouse dendritic cells present in the subepithelial
dome of Peyer’s patches where it blocks IL-22 and promotes
bacterial uptake by modulating gene expression in the follicle-
associated epithelium (7). rIL-22BPi2 administration to mice
before sepsis induction was found to attenuate bacterial load and
organ failure at the site of infection (20). The human IL22RA2
gene locus contains single nucleotide polymorphisms (SNPs) that
are associated with cancer remission (21) and risk to contract
multiple sclerosis (MS) (22–25). In a mouse model for MS,
experimental autoimmune encephalomyelitis (EAE), deletion of
the Il22ra2 gene conferred a less severe course of disease (26).
Perriard et al. (27) demonstrated that expression of IL-22 and
IL-22BP are dysregulated in MS patients. Risk SNPs acting as
expression- or splicing-quantitative trait loci (e- or sQTLs) may
affect overall expression levels of gene transcripts or enhance
splicing of alternative transcripts, respectively (28). It remains to
be investigated if and to what extent such effects are exerted by
risk SNPs on IL22RA2 transcripts.
Targeting of IL-22 may have therapeutic potential for
treatment of diseases in which the IL-22 signaling pathway is
implicated including inflammatory bowel disease, inflammatory
skin disorders or multiple sclerosis. Currently, blocking IL-
22 with anti-IL-22 monoclonal antibody is in in phase
2a trial for treatment of atopic dermatitis (29); moreover,
delivery of the murine IL22ra2 gene by cationic micelles has
displayed promising potential for colon cancer therapy (30). The
therapeutic potential of the two other human IL-22BP isoforms
is as yet poorly understood.
In order to pave the way for a better understanding of
the specific contribution of the individual IL-22BP isoforms
to neuro-inflammation and MS, we characterized IL22RA2
transcripts in myeloid cells and linked mRNA expression to
secreted immunoreactive protein. We performed a biochemical
characterization of the three human IL-22BP isoforms in
recombinant cell systems. We identified factors involved in
their folding and secretion through identification of their
interactomes. We demonstrate that IL-22BPi1 is incapable of
binding IL-22 in bio- and co-folding assay and is retained
intracellularly through interactions with ER. We show that this
retention induces a strong unfolded protein response (UPR)
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leading to increased protein levels of GRP78 and GRP94. In
addition, we report that secretion of IL-22BPi3 is independent
from the ER chaperones GRP78 and GRP94. Thus, IL-22BPi1




IL22RA2v2 myc-FLAG tag and IL22RA2v3-FLAG tag
plasmids were, respectively purchased from Origene (RC219095)
and GenScript (Ohu00490). Pfu DNA polymerase was purchased
from Thermo Scientific (EP0501) and all restriction enzymes
were from New England Biolabs. Taq DNA polymerase
was from Thermo Fisher Scientific (10342020). Vectors
expressing C-terminal Myc-FLAG-tagged IL22RA2v2, IL-2,
IL-4, IL-10, IL-17, IL-22, IFN-γ, and GRP94 were from
Origene. Deglycosylations were performed using Endo H
(New England Biolabs, P0702s) and PNGaseF (New England
Biolabs, P0704s). IFN-γ was from Peprotech (AF30002; used
at 500 pg/ml), LPS from Sigma (L2630; 200 ng/ml) CpG
(ODN2216; 1µg/ml) and Poly I:C (1µg/ml) from Invivogen.
Anti-IL-22BP antibodies used throughout this work are listed in
Supplementary Table 1. Further antibodies used are provided in
the corresponding method sections. Predesigned TaqMan assays
for IL22RA2 (Hs00364814_m1), IL12B (Hs01011519_m1),
IL6 (Hs00174131_m1) and ACTB (Hs99999903_m1) were
from Thermo Fisher Scientific. Predesigned SYBR Green
primers for GRP94 (QT00046963), ERDj3 (QT00042560) and
GRP170 (QT00046214) were from Qiagen. Predesigned SYBR
Green primers for HPRT1 (Hs.PT.58v.45621572), IL22RA2
(Hs.PT.58.40811), HERP (Hs.PT.58.21409911), CHOP
(Hs.PT.58.3400360), GRP78 (Hs.PT.58.22715160), ERP44
(Hs.PT.58.4529248), and PPIB (Hs.PT.58.40291667) were from
IDT. Additional in-house designed SYBR Green primers
were from IDT and their sequences are represented in
Supplementary Table 2. For silencing of IL22RA2 we used On-
TARGETplus SMARTpool human IL22RA2 siRNA (Dharmacon;
L-007974-00-0005) and non-targeting control siRNA, both used
at 100 nM unless otherwise specified. Polymer-based transfection
reagents Viromer BLUE (VB-01LB-00) and GREEN (VG-
01LB-03) were from Lipocalyx. SubAB and a non-proteolytic
mutant thereof with a S272A substitution in the A subunit
(designated Mut SubAB) were purified from recombinant E. coli
as previously described (31).
CD14+ Monocyte Isolation, Maturation and
Cell Culture
Buffy coats were obtained from healthy donors from the
Basque Biobank (http://www.biobancovasco.org/en/) with the
approval of the Ethics Committee of Clinical Investigation of
the Basque Country (CEIC-E) based on provision of a detailed
study protocol. Peripheral blood mononuclear cells (PBMCs)
were separated through Ficoll-Paque (GE Healthcare) gradient
centrifugation. Monocytes were isolated from PBMCs by CD14
positive selection usingMACSCD14microbeads (Miltentyi, 130-
050-201). To differentiate isolated monocytes into immature
monocyte-derived dendritic cells (moDCs), monocytes were
cultured at 1 × 106 cells/ml density in Mo-DC medium, a
commercially available moDC differentiation medium based on
RPMI 1640 medium containing FBS, L-glutamine, IL-4 and GM-
CSF (Miltenyi, 130-094-812), for 6 days, or as indicated, and
an equal volume of fresh Mo-DC medium was added on day 3.
Maturation of moDCs was induced by adding IFN-γ (Peprotech,
AF-300-02; 500 pg/ ml) for overnight priming (16 h) followed
by late addition of LPS for 6 hrs (Sigma, L6143; 2µg/ml) to the
culture or, alternatively by addition of CpG (Miltenyi, 130-100-
243; 1µg/ml) or LPS/Poly(I:C) (Sigma, P1530; 1µg/ml) for 6 h.
HEK293, HeLa and A549 were cultured in DMEM supplemented
with 10% FBS and 2mM L-glutamine; U937 cells were cultured
in RPMI supplemented with 0.05mM β-mercaptoethanol, 10 %
FBS and and 2mM L-glutamine.
FACS of Monocytes and Flow Cytometry of
moDCs
PBMCs were obtained from freshly isolated buffy coats of
healthy donors using Ficoll-Hypaque gradient (ThermoFisher).
Monocytes were isolated using Pan Monocyte Isolation kit
(Miltenyi) following manufacturer’s instructions. Monocytes
were labeled for 15min in dark conditions with PE conjugated
anti-human CD14 (Miltenyi, 130-110-519) and FITC conjugated
anti-human CD16 (Miltenyi, 130-106-703) in sorting buffer
(HBSS, FBS 2%; EDTA 2mM, HEPES 25mM) prior to
cell sorting. Monocyte subpopulations were sorted in a
FACSJazz (BD) cell sorter following the strategy described
in Supplementary Figure 1. For assessing maturation state,
moDCs were labeled with Mo-DC Differentiation Inspector
(Miltenyi, 130-093-567), a commercially available mouse
monoclonal conjugated antibody cocktail containing CD14
antibody conjugated to fluorescein-isothiocyanate (FITC;
clone Tük4, isotype: mouse IgG2a), CD83 conjugated to
allophycocyanin (APC; clone: HB15, isotype: mouse IgG1), and
CD209 conjugated toR-phycoerythrin (PE; clone DCN-47.5.4,
isotype: mouse IgG1) or isotype control cocktail containing
monoclonal mouse IgG2a-FITC, IgG1-PE, and IgG1-APC
conjugates in corresponding concentrations (Miltenyi, 130-
093-567) following manufacturer’s instructions. Gating strategy
consisted of a size-complexity discrimination of moDCs
and selection of single cells prior to label discrimination.
CD14 (FITC) and CD209 (PE; which corresponds to DC-
SIGN) were used to select moDCs (CD14−CD209+). CD209
(PE) and CD83 (APC) were used to discriminate between
immature (CD209+CD83−) and mature (CD209+CD83+)
cells. Raw CD209/CD83 flow cytometry data of immature and
mature moDCs are provided in Supplementary Figure 2. Raw
CD14/CD209/CD83 flow cytometry data of immature and IFN-
γ/LPS-matured CD16−CD14+ and CD16+ monocyte-derived
DCs and corresponding cytokine measurements by qPCR are
available in Supplementary Data 1.
RT-PCR, qPCR and Conventional PCR
Reverse Transcriptase PCR(RT-PCR)
RNA was extracted with TRI Reagent (Sigma, T9424) following
manufacture’s protocol, and quantified using Nanodrop 2000c
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spectrophotometer (Thermo Scientific). Five hundred Nano
gram of RNA were reverse-transcribed to cDNA according to
manufacturer’s instructions (Thermo Scientific, 4368814) in a
volume of 20 µl on a Veriti thermocycler (Applied Biosystems).
Quantitative PCR (qPCR)
One microliter of cDNA was amplified by qPCR using primers
and SYBR Green (Thermo Scientific, 4385616) or Taqman
probes on a 7500 Fast Real Time PCR System (Applied
Biosystems). The primers used in each figure are indicated in
Supplementary Table 2. qPCR with amplification program for
SYBR Green was: one cycle at 95◦C for 20 s, followed by 40
cycles at 95◦C for 3 s and 60◦C for 30 s, and concluding with a
dissociation stage. qPCR with amplification program for Taqman
was: one cycle at 50◦C for 2min, followed by one cycle at 95◦C
for 10min. This was followed by 40 cycles at 95◦C for 15 s
and 60◦C for 1min and concluded with a dissociation stage.
The threshold for detection was set within the linear phase of
the logarithmic amplification plot. All targets were measured in
technical duplicates or triplicates. Quality negative controls were
included in all runs, and melting temperatures were analyzed
for SYBR Green qPCRs; as well, qPCR products sizes were
analyzed by gel electrophoresis. Levels of expression of each gene
were normalized to the housekeeping genes used, as indicated,
and expressed as 2−11Ct relative to the average of the control
group.
Conventional PCR
Conventional PCR was carried out on a Veriti thermocycler
(Applied biosystems). All PCR reactions were performed using
Taq DNA polymerase (Thermo Fisher Scientific, 10342020) in
the presence of dNTP’s (Thermo Fisher Scientific, 10297018).
Ten microliter of each cDNA product were amplified with the
following amplification program: initiation step, 94◦C for 45 s,
followed by 35 cycles of [denaturation step at 94◦C for 45 s;
elongation step in which annealing temperatures were adjusted to
the melting temperatures of each pair of primers, and elongation
step at 72◦C for 10 s]. A final extension step was performed at
72◦C for 10min. Products were run on 2% agarose (w/v) gels
(Agarose: Sigma, A9539) in Tris acetate-EDTA buffer with SYBR
Safe. Gels were visualized with the ChemiDoc Imaging System
(Bio-rad).
Cloning Procedures
Cloning of IL22RA2v1 Into pCMV6-Entry Vector
The cDNA coding for IL-22RA2v1 (isoform-1) was initially
amplified with Pfu polymerase from two overlapping fragments
with primers including terminal MluI and SgfI restriction sites
starting from retrotranscribed RNA extracted from immature
moDCs. PCR products were digested with MluI and SgfI
restriction enzymes and cloned into pCMV6-Entry vector.
Subcloning of IL22RA2v2 Into TET-Express System
The multiple cloning site of pTRE3G-BI-mCherry vector
(Clontech, 631333) was modified by including the following
sequence by oligo overlapping: BamHI-MluI-BspEI-FLAG-Stop-
Stop-EaglI. The IL22RA2v2 sequence was amplified from the
original PCMV6-Entry vector (Origene RC219095) with Pfu
polymerase, digested with BglII and MluI, and cloned into the
modified pTRE3G vector.
Cloning IL22RA2v1 Alternatively Spliced Exon Into
IL-2
Exon-4 in IL-22RA1-containing pCMV6-entry vector was
amplified with FW IL-2 and RV IL-2 cloning primers using
Pfu polymerase. Both the purified fragment of 124 bp and IL-2
vector were digested usingXbaI and purified. To avoid religation,
the vector was dephosporylated with shrimp alkaline phospatase
(SAP; Promega M820A; 15min 37◦ and 15min at 65◦). Ligation
with T4 DNA Ligase (New England BioLabs; M0202S) and
transformation of Mach 1-competent cells (Thermo; C862003)
were performed. All constructs were verified to be error free by
sequencing on both strands.
Transient Transfection, Protein Extraction
and Cell Manipulations
Transient transfections of HEK293 or HeLa cells were conducted
at 60–70% confluency using MACSfectin Reagent (130-098-
412, Miltenyi Biotec). For TETexpress-inducible system,
transactivator was added 24 h after transfection following
manufacture instructions (Clontech). At indicated times,
medium was removed and stored at −80◦C in presence of
protease inhibitors (Roche, 11697498001); cells were collected
and washed three times with PBS before addition of lysis buffer
(300mM NaCl, 50Mm NaH2PO4 pH 8, 1% Triton X-100) or
RIPA buffer (25mM Tris/HCl 150mM NaCl, pH 7.6, 1% NP
- 40, 1% sodium deoxycholate, 0.1% SDS) as indicated, both
containing protease inhibitors cocktail. Cell lysis was done
for 30min on ice followed by centrifugation at 21.000 × g
at 4◦C. Protein fraction was collected from the supernatants
and immediately processed for immunoprecipitation or stored
at −80◦C for further analysis. Protein concentrations were
determined using Bradford (Bio-Rad, 5000006) or BCA (Bio-
Rad, 23225) colorimetric assays. Absorbance was measured with
Varioskan Flash (Thermo Fisher Scientific). Conditioned media
was also collected and proteasome inhibitors cocktail added.
For acetone precipitations, 4 h before collection, conditioned
medium was removed and cells were carefully washed three
times with pre-warmed serum-free medium (Lonza, 12–764Q)
supplemented with 2mM L-glutamine. Serum-free medium
(SFM) was added and left for that period in culture conditions.
Four volumes of ice-cold acetone were added to the medium,
mixed and incubated for 15min on ice. Samples were centrifuged
at 12,000 × g for 10min at 4◦C. Supernatants were carefully
removed and precipitates were resuspended in loading buffer
or in water for enzymatic treatment. Proteasome inhibition:
Protein degradation was studied as published (32). Briefly, 24 h
after transfection a mixture of proteasome inhibitors (5µM
lactacystin, 5µM MG132, and 1mM epoxomycin) was added
and 18 hrs later, cells were harvested, lysed and analyzed by
immunoblotting. Cell fractionation: Cell fractionation was
carried out according to Holden and Horton protocol (33).
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Immuno-/Affinity Purification
Three different purification resins were used depending on the
protein of interest. Anti-FLAG resin (GenScript, L00432), anti-
c-Myc resin (Sigma, E6654) and S-protein agarose (Millipore,
69704) were used following manufacturers’ instructions. All
purifications were performed o/n at 4◦C on a rotating wheel.
Samples were washed six times with equilibration buffer (50mM
Tris, 150mM NaCl, pH 7.4, 0.1% Tween 20). Elution buffer
(0.1M glycine, 0.5% SDS, 0.15M NaCl pH 2) was then added to
the resin, samples were incubated 5min at RTwith gentle mixing,
resins were centrifuged at 300 × g for 2min, supernatants were
carefully collected avoiding the resin absorption and pH was
adjusted adding 1:10 of 1M Tris pH 10.
IL-22BP Bioassay
IL22BPi1, IL22BPi2 and IL-22 were independently transfected
into HEK293 as previously mentioned. After 24 h, secreted
fractions of IL22BPi1 and IL22BPi2 were quantified by ELISA
(see below). Different dilutions and exposure times of IL-22 were
assessed to A549 to stablish the optimal time and dose-response
of STAT3 phosphorylation, which was measured by western blot.
Equal amounts of IL22BPi1 or IL22BPi2 were mixed with the
selected volume of IL-22 and filled to the same final volume with
conditioned media. Mixture was incubated at 37◦C for 1 h prior
to addition to A549. After the exposure time, the A549 protein
fraction was extracted and analyzed by immunoblot.
IL-22BP Isoform Interactome Analysis
Protein interactomes of IL-22BP isoforms were purified by anti-
FLAG affinity chromatography as described above, and eluted
fractions were resolved on 10% precast SDS-PAGE gels (Bio-
Rad, 4561034). Gels were silver stained following manufacture’s
protocol (Thermo Fisher Scientific, 24612), washed, and gel
bands were sliced. Each band was digested with trypsin following
a standard in-gel digestion protocol based on Shevchenko et al.
(34) with minor modifications (34). The resulting peptides were
resuspended in 0.1% formic acid, separated using online NanoLC
and analyzed using electrospray tandem mass spectrometry.
Peptide separation was performed on a nanoACQUITY UPLC
system connected to a SYNAPT G2-Si spectrometer (Waters,
Milford, MA, USA). Samples were loaded onto a Symmetry
300 C18 UPLC Trap column of 5, 180µm × 20mm (Waters,
Milford, MA, USA), connected to a BEH130 C18 column of 1.7,
75µm × 200mm (Waters, Milford, MA, USA). The column
was equilibrated in 3% acetonitrile and 0.1% FA. Peptides
were eluted at 300 nL min−1 using a 60-min linear gradient
of 3–50% acetonitrile. A SYNAPT G2-Si ESI Q-Mobility-TOF
spectrometer (Waters, Milford, MA, USA) equipped with an
ion mobility chamber (T-Wave-IMS) for high definition data
acquisition analyses was used for the analysis of the peptides.
All analyses were performed using electrospray ionization in
a positive ion mode. Data were post-acquisition lock-mass
corrected using the double-charged monoisotopic ion of [Glu1]-
fibrinopeptide B. Accurate LC-MS data were collected in
HDDA mode, which enhances signal intensities using the ion
mobility separation. Mascot searching engine (MatrixScience)
against Uniprot/Swissprot human database was performed.
Searching parameters were delimited as follows: Peptide mass
tolerance of 10 ppm and 0.2-Da fragment mass tolerance
were. Carbamidomethylation of cysteines was selected as the
fixed modification and oxidation of methionine as a variable
modification for tryptic peptides. Proteins identified with at
least two peptides with an FDR < 1% were kept for further
examination.
Immunoblotting
Equal quantities of cell lysates, volumes of eluted fractions,
or conditioned media were loaded on SDS-PAGE gels (10 or
12%) and transferred to PVDF membranes for immunoblotting;
blots were blocked with 2% casein o/n at 4◦C and subsequently
incubated with primary antibodies o/n at 4◦C. Blots were washed
with TBST buffer 3 times for 10min each. HRP-conjugated
secondary antibodies were incubated for 1 h. Immunoreactivity
was assessed using a chemiluminescence substrate (Bio-Rad,
1705061) andmeasured using a ChemiDoc Imaging System (Bio-
rad). Densitometry values were normalized to a control loading
protein or to the Ponceau staining) using Image Lab Software
(Bio-Rad). Primary antibodies were anti-FLAG (Rb, Proteintech;
20543-1-AP; 1:1000, &ms, Sigma; F1804), anti-GRP94 (Rt, Enzo;
ADI-SPA-850; 1:1000), anti-IL-22BP (Gt, R&D Systems; AF1087
and BAF1087; 1:1000 each, and Ms, Proteintech; 66190; 1:1000),
anti-pSTAT3 (Rb, R&D Systems; AF4607; 1:1000), anti-actin
(Rb, Sigma-Aldrich; A2066; 1:100), anti-tubulin (Ms, GenScript;
A01490; 1:1000), anti-GAPDH (Ms, Millipore; ABS16; 1:2000),
anti-GRP78 (Gt, R&D Systems; AF4846; 1:1000), anti-GRP170
(Ms, IBL; 10301; 1:100), anti-CNX (Rb, Enzo; ADI-SPA-860;
1:1000), anti-ERdj3 (Rb, Proteintech; 15484-1-AP; 1:1000), anti-
KDEL (Ms, Enzo; ADI-SPA-827; 1:1000), anti-histone H3 (Rb,
Cell Signaling; 4499; 1:2000), anti-PPIB (Rb, Abcam; 16045;
1:500). All HRP-conjugated secondary antibodies were purchased
from Jackson immunoResearch.
IL22BP ELISA
An in-house ELISA was developed for sensitive IL-22BP
detection. High binding ELISA plates (Sarstedt, 82.1581.200)
were coated with 100 µl of 0.5µg/ml antigen-purified
goat polyclonal IL-22BP antibody (R&D systems, AF1087;
immunogen used was recombinant human IL-22BP Thr22-
Pro231 coinciding with mature IL-22BPi2) in coating solution
(50mM Tris/HCl, 150mM NaCl, pH 8,5) and incubated o/n
at 4◦C. The next day, coating mix was removed followed by
three washings steps with 200 µl of washing solution (50mM
Tris/HCl, 150mM NaCl, 0.05% Tween 20, pH 7,4) each; 200
µl of blocking solution (50mM Tris/HCl, 150mM NaCl, 0.1%
casein, pH 7,4) was added to the wells and incubated o/n at
4◦C. Blocking solution was removed followed by three washings
with 200 µl of washing solution each. Semilog dilutions of
biosamples were added to the plate (100 µl each) prediluted 1:10
in assay buffer (50mM Tris/HCl, 150mM NaCl, 0.1% casein,
0.05% Tween 20, pH 7,4), with recombinant IL-22BP human
protein-His tag (Sino biologicals, 11025-H08H) used as standard.
Samples and standard were incubated 2 h at 37◦C. Samples were
removed and wells were washed six times with 200 µl of
washing solution each. Antigen-purified goat polyclonal IL-22BP
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biotinylated antibody (R&D Systems, BAF1087) was added to
each well in assay buffer at 0.5µg/ml dilution and incubated
for 1 h at 37◦C followed by six washings. Biotinylated detection
was performed with streptavidin conjugated to horseradish
peroxidase (R&D systems, DY998) diluted in assay buffer 1:200
for 1-h incubation time at 37◦C. Streptavidin-HRP mixture was
removed and plates were washed six times. ELISA was developed
with 95 µl of TMB substrate solution (Thermo Scientific, 34028)
in a 30min incubation period. Reaction was stopped with 95
µl of 2M H2SO4 and absorbance was read at 450 nm using
Varioskan Flash (Thermo Scientific). Preliminary experiments
demonstrated that the AF1087 or BAF1087 antibodies detected
each of the three IL-22BP isoforms in western blot in the
conditioned media of individually transfected cells.
Immunofluorescence Microscopy
Cells in coverslips were fixed with cold 4% paraformaldehyde
for 10min and washed 3 times with PBS. Microscopy buffer
containing 0.2% Triton X-100 and 3% BSA in PBS, pH 7.4 was
used in all subsequent steps. Permeabilization was performed
and non-specific staining was blocked with microscopy buffer
for 30min. Primary antibodies were incubated for 1 h at RT
in microscopy buffer. Then cells were washed 3 times for
10min with PBS. Secondary antibodies were incubated in
dark conditions for 1 h at RT in microscopy buffer. All the
downstream steps were also performed in dark conditions.
Following secondary incubations, coverslips were incubated with
PBS containing DAPI for 5min at RT followed by two washes
with PBS for 10min. Finally, coverslips were mounted on glass
slides using Fluoromont (Southern Biotech 0100-01). Images
were acquired in a Leica TCS STED CW SP8 super-resolution
microscope. For confocal immmuofluorescence microcroscopy,
we used the following antibodies: anti-IL22RA2 (R&D; AF1087
and BAF1087, 1:20 each), anti-IL22RA2 (Proteintech; 66190-1-
Ig), anti-TGOLN (Atlas; HPA012723-100ul, 1:500), anti-ERp72
(Enzo; ADI-SPS-720-F; 1:500), donkey anti-goat A647 (Jackson
ImmunoResearch; 705-605-147; 1:500), Streptavidin DyLight
488 (Tebu-bio; 039S000-41; 1:4000), donkey anti-rabbit A647
(Jackson Immunoresearch; 711-605-152; 1:500), as well as DAPI
(Sigma; 10µg/ml).
Statistical Analysis
Statistical analysis was performed for quantitative assays with
the GraphPad Prism software, specific tests are included in the
legends to figures.
RESULTS
IL-22BP Protein Levels Reflect IL22RA2
mRNA Levels Produced by
Monocyte-Derived Dendritic Cells
The three IL22RA2 mRNA variants were detected in immature
moDCs (primary monocytes cultivated 6 days in differentiation
medium (DM) containing granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-4) by RT-PCR using
both best coverage (BC; i.e., primers designed to detect
the three isoforms by annealing to shared regions in the
expressed products) and isoform-specific designed primers,
and products were verified via agarose gel electrophoresis
(Figure 1A). Expression levels of the three transcripts increased
in the presence of AM580, a retinoic acid receptor agonist,
in agreement with Martin et al. (5) (Figure 1A). Maturation
of moDCs with CpG, IFN-gamma + LPS or polyI:C + LPS
decreased IL22RA2 gene expression (Figure 1B), with the extent
of the decrease proportional to that of the degree of maturation
(Supplementary Figure 2). Given that the three isoforms share
the same functional signal peptide and should therefore be
secreted, and that secretion of IL-22BP by natural producer
cells has not been reported in the literature, we set out to
demonstrate IL22BP immunoreactivity in both cell lysates and
the culture medium by means of an in-house developed antigen-
purified goat polyclonal ELISA (see section Materials and
Methods) capable of detecting 30 pg/ml recombinant IL22BP.
In immature moDCs cells, strongly increasing levels of IL22RA2
mRNA were observed by qPCR over a 10-day cultivation period
(Figure 1C), but corresponding IL-22BP levels in the culture
medium of these moDCs as measured by ELISA increased only
modestly (Figure 1C). In western blot, intracellular IL-22BP
immunoreactive protein bands were detected with molecular
masses extending from around 38 to 40 kDa that were increased
in AM580-treated moDCs (Figure 1D). However, individual
secreted IL-22BP isoforms could not be resolved in culture
medium of moDCs (Figure 1D) or following concentration of
medium with acetone (Supplementary Figure 3), and this may
be due to the low levels of secreted IL-22BP as detected by ELISA.
Additional experiments to detect IL-22BP in the monocytic U937
cell line [reported to produce IL22RA2 transcripts in (13)] or
moDC by western blot using distinct anti-IL-22BP antibodies
are presented in Supplementary Figure 3. Therefore, we used
recombinant expression vectors transfected into HEK293 cells to
gain more insight into the mechanisms governing secretion of
IL-22BPi1, 2 and 3. Vectors expressing IL-22BPi2 and -BPi3 were
commercially available, an expression vector for IL-22BPi1 was
constructed frommoDCmRNA as described in sectionMaterials
and Methods.
IL-22BPi1 Is Poorly Secreted, Retained in
the ER and Degraded by the Proteasome
C-terminally myc-FLAG-tagged IL-22BPi1, IL-22BPi2 and IL-
22BPi3 expression plasmids were individually transfected into
HEK293 cells, and secreted IL-22BP levels were subsequently
measured by ELISA. While high levels of IL-22BPi2 were
observed in the culture medium (Figure 2A), those of both IL-
22BPi1 and IL-22BPi3 were much lower, even if transfection
efficiencies as measured by RT-qPCR through quantification of
mRNA levels were similar (Figure 2A). Conversely, intracellular
levels of IL-22BPi1, but not of the other two isoforms, increased
over time after transfection (Figure 2A, inset) suggesting that the
former’s poor secretion was related to preferential intracellular
accumulation. In immunofluorescence microscopy, IL-22BPi1
formed a perinuclear diffuse granular staining pattern tending to
co-localize with the endoplasmic reticulum (ER) marker ERp72
but not with the trans-Golgi marker TGOLN2 (Figure 2B).
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FIGURE 1 | IL-22BP protein and mRNA levels in monocyte-derived DCs. (A) (Upper left) Diagram showing exons with the primer-binding positions for IL22RA2 variant
discrimination strategy. (Lower left) Expression of IL22RA2v1, v2, and v3 in moDC after 6 days of culture in differentiation medium (DM) ± AM580, a retinoic acid
receptor agonist, by RT-PCR. IL22RA2v2 expression vector was used as positive control for IL22RA2v2 expression. (Upper right) Expression of IL22RA2 variants in
moDC following 6 days of culture in DM ± AM580 by RT-qPCR using the isoform-specific primers indicated in the left diagram (mean ± SEM; n = 3) relative to the
housekeeping gene GAPDH. (B) Effect of different maturation stimuli (CpG and LPS + IFN-γ or Poly I:C) on IL22RA2, IL12B, and IL6 expression in moDC after 6 days
of culture in DM by RT-qPCR using Taqman probes relative to the housekeeping gene ACTB. Extent of maturation is represented as percentage of CD83+
fluorescence by flow cytometry. Data showing representative experiment of 3 performed. (C) IL-22BP secretion by moDC cultured in DM detected by ELISA
corresponds to IL22RA2 mRNA expression levels analyzed by RT-qPCR using Taqman probes and both increase over the cultivation period (mean ± SEM, n = 2).
(D) Cell lysates (CL) of moDCs and conditioned media (CM) were harvested after 6 days in DM ± AM580 and immunoblotted for detection of IL-22BP (IL-22BP
antibody 1) using tubulin as a loading control, IL22RA2 mRNA expression relative to the mean of the housekeeping genes GAPDH and ACTB was measured by
RT-qPCR using pre-designed SYBR Green primers from the same cells. Representative experiment out of three performed. All primers used are listed in
Supplementary Table 2.
IL-22BPi2 and IL-22BPi3, in contrast, were mainly visible
as densely staining deposits located on one side outside the
nucleus that co-localized with TGOLN2 but less so with
ERp72. These data imply efficient export of IL-22BPi2 and
IL-22BPi3 from ER to the Golgi apparatus, but not of IL-
22BPi1 that seems to be retained predominantly within the
ER.
Next, we compared the detection of secreted IL-22BPi2 with
a series of cytokines that were, like IL-22BPi2, expressed with
C-terminal myc-FLAG tags. In contrast to these cytokines, IL-
22BPi2 was not detected in the cell culture medium by western
blotting using an anti-FLAG antibody (Figure 2C). However,
secreted IL-22BPi2 and IL-22BPi3 were detected with anti-
FLAG after concentration of culture medium with acetone (AP),
while IL-22BPi1 was not (Figure 2D). Treatment of cell lysates
with peptide N-glycosidase F (PNGase F, which cleaves all
N-linked glycans) or endoglycosidase H (Endo H, which cleaves
within the chitobiose core of high-mannose but not complex
glycans), revealed that the three intracellular isoforms contain
high-mannose-type N-glycans compatible with 3 predicted
N-glycosylation sites for IL-22BPi1 and IL-22BPi2, and 1 for
IL-22BPi3 (NetNGlyc 1.0 server; Figure 2E). Compared to the
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FIGURE 2 | Differential secretion, intracellular retention and degradation by the proteasome of IL-22BP isoforms. Data refer to HEK293 cells transiently transfected for
24 h unless otherwise specified. (A) HEK293 cells were transiently transfected with expression vectors encoding IL-22BPi1, BPi2, or BPi3. Intracellular and secreted
IL-22BP protein levels were measured by WB (FLAG Ab) and ELISA, respectively. Transfection efficiency was measured by IL22RA2 RT-qPCR relative to the
housekeeping gene GAPDH (mean ± SEM; n = 3). (B) Confocal microscopy of IL-22BP isoforms (green, IL-22BP Ab 4 with either ERp72 or trans-Golgi marker
TGOLN2 (red) in transfected HEK293 cells; cells were counterstained with DAPI. (C) Secreted recombinant IL-22BPi2 is not detected by WB in unconcentrated
conditioned media (CM). Various cytokine expression vectors, as indicated, were transiently transfected and CM were collected and immunoblotted for FLAG.
(D) Detection of IL-22BP isoforms in cell lysates (CL) and acetone-precipitated CM (AP) by FLAG Ab. Secreted IL-22BPi2 was treated with PNGase F or Endo H.
(E) Intracelullar isoforms of IL-22BP were treated with PNGase F or Endo H and detected by FLAG Ab. (F) HEK293 cells were transfected for 24 h with expression
vectors for either IL-2 or IL-2EX4. The latter was generated by subcloning exon-4 from IL22RA2v1 into the open reading frame of IL-2 through its unique Xba1
position. Detection of resulting proteins in AP, CL, CM by FLAG Ab. (G) HEK293 cells were transiently transfected with the same expression plasmids as in (A) or
IL-2EX4; 24 h later, cells were treated with a mix of proteasome inhibitors (PI) (5µM lactacystin, 5µM MG132, and 1mM epoxomicin), and 18 h later cells were lysed
and immunoblotted for FLAG using GAPDH as a loading control. All data are from at least 3 independent experiments.
cell-associated protein, secreted IL-22BPi2 gained around 8 kDa
in Mr (56 vs. 48 kDa) and was resistant to Endo H, but not
PNGase F, indicating the sole presence of complex N-glycans
and thus transit via Golgi (Figure 2D, rightmost panel). We
also found that the secreted deglycosylated protein was more
sensitive to detection in western blot than the glycosylated one
(Figure 2D). In order to determine whether poor secretion of
IL-22BPi1 is due to the presence of an extra 32-amino acid
stretch coded by the alternatively spliced exon that is absent in
IL-22BPi2 and IL-22BPi3, we cloned this sequence into IL-2,
an efficiently secreted protein (Figure 2C). We inserted the
sequence into the uniqueXbaI site of IL-2 (position 233 following
ATG initiation codon), maintaining the integrity of the original
reading frame after the insertion as is the case in IL-22BPi1. IL-2,
but not IL-2EX4, was detected in acetone precipitates of culture
medium while the latter was enriched in cell lysates (Figure 2F).
Biochemical fractionation of transfected cells to generate separate
cytosolic, membranous organelles (MO), nuclear and insoluble
fractions followed by immunoblot, revealed that IL-2EX4 similar
to the three IL-22BP isoforms, was detectable in the MO fraction,
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FIGURE 3 | IL-22BPi1 does not interact with IL-22 or IL-22BPi2. (A) A549 cells were exposed for 30 minutes to dilutions of IL-22-containing culture medium (CM)
previously produced by IL22-transfected HEK293 cells. A549 cell lysates (CL) were immunoblotted for pSTAT3 and tubulin as loading control. The relative
densitometry of pSTAT3 normalized to that of tubulin is also represented. (B) A549 cells were treated with the optimum IL-22 dilution from A (1/512) for different
(Continued)
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FIGURE 3 | periods of time, lysed and immunoblotted for pSTAT3. An unspecific protein band (u.p.) was used as loading control. (C) IL-22BP concentration in
conditioned medium (CM) of transfected HEK293 cells was measured by ELISA, and the indicated amounts in nanograms (ng) of IL-22BPi1 or IL-22BPi2 were
pre-incubated for 1 h at 37◦C with the selected IL-22 concentration from (A). A549 were exposed to the pre-incubated combinations for 20min. An excess of
IL-22BPi2 was used as phosphorylation blocking control (lane 3). Cells were lysed and immunoblotted for pSTAT3 and actin as loading control. (D) HeLa cells were
co-transfected with the indicated expression plasmids, 24 h later cells were lysed and the CM was subjected to acetone precipitation (AP), and proteins were
immunoblotted for FLAG. Intracellular IL-22BPi1 is indicated with dark purple arrows, intracellular and secreted IL-22BPi2 is indicated with green arrows, and
co-expressed IL-22 and IL-17 are also indicated. (E) Conditioned media (CM) from 3 independent experiments, in which expression vectors for the three IL-22BP
isoforms were individually transfected into HEK293 cells together with either IL-17 or IL-22 expression vectors or an empty vector control (EV), were analyzed 24 h
after transfection by ELISA for IL-22BP (mean ± SEM; n = 3; **p < 0.01 by unpaired t-test). (F) IL-22BPi1 does not interact with IL-22BPi2. IL-22BPi1-MF expression
plasmid containing Myc and FLAG tags was co-transfected with an inducible pTRE3G-based vector expressing IL-22BPi2 with only a FLAG tag. After 24 h, cells were
induced for IL-22BPi2 production by adding Tet-Express activator to the medium for a further 24 h. Cells were lysed and immunoprecipitated with anti-Myc agarose,
the flow-through fractions were then further subjected to FLAG immunoprecipitation. CL and eluted fractions were immunoblotted for FLAG.
and that none of these proteins sedimented in the insoluble
fraction as aggregates (Supplementary Figure 4).
We asked whether the poor secretion of IL-22BPi1 and
IL-2EX4 could be due to high intrinsic tendency to misfold.
Misfolded proteins are known to be intercepted by the
endoplasmic reticulum quality control system (ERQC) and
delivered for ER-associated degradation (ERAD) by the
proteasome (35). Thus, increased intracellular protein levels
upon pharmacological inhibition of the proteasome point to
misfolding reactions taking place. Figure 2G shows increased
levels of IL-22BPi1 and IL-2EX4 and, noteworthy, also of
IL-22BPi2 upon treatment of transfected cells with proteasome
inhibitors, while IL-22BPi3 appeared not to be affected.
IL-22 “Chaperones” the Secretion of
IL-22BPi2 and IL-22BPi3 but Not of
IL-22BPi1
We tested the capacity of IL-22BPi1 to interact with IL-22 in both
a bioassay and a co-folding assay. The bioassay was based on
inhibition by IL-22BP of IL-22-induced STAT3 phosphorylation
in the A549 cancer cell line. First, we determined both the
largest dilution of conditioned medium (CM) from HEK293
transfected with an IL-22 expression vector still able to induce
maximal phosphorylation of STAT3 in A549 cells, and the time
point after addition of IL-22 at which STAT3 phosphorylation is
most pronounced (i.e., dilution 1/512 and 20min, respectively;
Figures 3A,B). Next, we assayed different concentrations of IL-
22BPi1 or BPi2 using CM of transfected HEK293 cells in which
IL-22BPi1 or IL-22BPi2 were determined by ELISA. Inhibition of
STAT3 phosphorylation by IL-22BPi2 was consistently observed,
while identical quantities of IL-22BPi1 did not impair IL-
22 mediated-STAT3 phosphorylation (Figure 3C). Under the
conditions of this assay, IL-22BPi1 does not seem to neutralize
the biological activity of IL-22.
For implementation of the co-folding assay we found
inspiration in earlier work done on IL-15 and IL-15Rα. In
dendritic cells, the α-chain of the IL-15 receptor acts as a
chaperone to stabilize IL-15 within the secretory tract against
proteasome degradation and to export it in a complex to
the membrane in its bioactive conformation (32, 36). IL-22BP
can be produced by a CD4+ subset of tissue-infiltrating T
lymphocytes (10), and given that various subsets of lymphocytic
cells (T and ILC) are known producers of IL-22 (1, 2), the
theoretical possibility exists that IL-22BP and IL-22 may occur
co-expressed in specific, yet to determine natural circumstances.
We thus asked if in the foldase- and chaperone-rich, folding-
permissive environment of the ER, a cytokine-receptor co-
assembly interaction may take place between IL-22 and
IL-22BPi1 that would rescue misfolding of the latter and
augments its secretion. As demonstrated for IL-15/IL-15Rα these
interactions can be reproduced in transfected human cell lines
(32). We co-transfected the three isoforms of IL-22BP each with
IL-22, or as negative control IL-17, a cytokine reported not
to bind any IL-22BP isoform (12). Interestingly, co-expression
of IL-22BPi2 and IL-22 strongly decreased intracellular and
increased secreted level of the former in western blot, suggestive
for productive interactions taking place enhancing folding and/or
transit of IL-22BPi2 (Figure 3D). However, increased secretion
in the presence of IL-22 was not seen for IL-22BPi1. In ELISA,
co-expression of IL-22 significantly enhanced secretion of IL-
22BPi2 and IL-22BPi3 but not that of IL-22BPi1 (Figure 3E). Co-
expression of IL-17 did not have any effect on IL-22BP isoform
levels (Figures 3D,E). In light of these findings, the extra 32-
amino acid sequence in IL-22BPi1 appears to have disrupted
this isoform’s capacity for interaction with IL-22. Given the
predominant ER localization of IL-22BPi1, its inability to bind
to IL-22 as well as its co-production with IL-22BPi2 in natural
producer cells (Figure 1), we asked whether IL-22BPi1 had the
capacity to physically interact with IL-22BPi2. We co-expressed
myc-FLAG-tagged IL-22BPi1 with FLAG-tag-only IL-22BPi2 in
HEK293 cells. Purification with anti-myc resin only recovered IL-
22BPi1 while further purification via anti-FLAG resin recovered
IL-22BPi2 from the flow-through fraction, suggesting that both
isoforms do not interact with each other (Figure 3F).
IL-22BPi1 and IL-22BPi2, but Not
IL-22BPi3, Bind the Substrate-Binding
Domain (SBD) of GRP78
In order to identify proteinaceous factors that may be responsible
for the intracellular retention of IL-22BPi1, we analyzed the
interactomes of the IL-22BP isoforms purified from Hela
and HEK293 cells by nLC MS/MS. A 75-kDa band was co-
purified from HEK293 cells, both with IL-22BPi1 and IL-
22BPi2 but not IL-22BPi3, that was identified as GRP78. We
observed that upon densitometric analysis of silver stained
gels, the relative amount of GRP78 co-purified with IL-22BPi1
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was more than 4 times higher than that associated with IL-
22BPi2 (Figure 4A). In HeLa or HEK293 cells, we reproducibly
identified by mass spectrometry 4 partners for IL-22BPi2,
i.e., GRP78, calnexin, GRP94 and GRP170, all of which are
ER-localized chaperone-type proteins (Figures 4A,B, inset and
Supplementary Data 2). In immunoblot validations, interaction
of IL-22BPi1 and IL-22BPi2 with GRP78, GRP94, GRP170, and
calnexin was seen, as well as with additional ER residential
FIGURE 4 | IL-22BPi1 and IL-22BPi2, but not IL-22BPi3, are bona fide client proteins of GRP78. (A,B) Identification of GRP78, GRP94, GRP170 and calnexin in
interactomes of IL-22BPi1 and IL-22BPi2. Silver-stained (S.S) gels of proteins (co-)immunoprecipitated (IP) with FLAG resins from HEK293 or HeLa cells transiently
transfected with the indicated expression plasmids or control empty vector (EV) are shown. Numbered arrow-heads indicate proteins identified by mass spectrometry
included in the inset summary Table (detailed information in Supplementary Data 2). Co-immunoprecipitated proteins without DSP treatment were immunoblotted
for detection by FLAG Ab. Asterisk, IL-22BPi1; empty arrowhead, IL-22; solid rhombus, IL-22BPi2; empty rhombus, IL-2EX. (Inset) Summary table with the mass
spectrometry results from protein identification. # Unique peptides, # Peptides, and # PSMs are: the number of peptide sequences unique to a protein group, the
number of distinct peptide sequences in the protein group and the total number of identified peptide sequences (peptide spectrum matches) for the protein.
(C) IL-22BPi1, IL-22BPi2 and IL-2EX4 bind the substrate-binding domain of GRP78. HEK293 cells were transiently transfected with the indicated constructs and 24 h
later were either treated with 100 ng/ml Mut SubAB or SubAB for 3 h. Cell lysates (CL) were co-immunoprecipitated with FLAG agarose. CL and IP proteins were
immunoblotted for FLAG or GRP78. (D) HEK293 cells were individually transfected with expression plasmids for the three IL-22BP isoforms together with either
GRP78 or GRP78T37G expression vectors or empty vector (EV). 24 h later secreted protein was measured by ELISA for IL-22BP (mean ± SEM; n = 3; *p < 0.05, **p
< 0.01 by unpaired t-test).
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proteins (Supplementary Figure 5). GRP78 was also identified
as the major interacting partner of IL-2EX4 but was not co-
purified with IL-2 or IL-22 (Figure 4B). GRP78 is an ER luminal
HSP70-type chaperone that binds newly synthesized proteins
during translocation into the ER, and contains two functional
domains, a nucleotide-binding domain (NBD) that binds ATP,
and a substrate-binding domain (SBD) that binds incompletely
folded client proteins. In order to find out whether the presence
of the extra sequence in IL-22BPi1 influenced the site of GRP78
with which it interacts, we treated cells with subtilase (SubAB), a
cytotoxin which is known to favor cleavage of newly synthesized
GRP78 to produce a 28-kDa C-terminal fragment containing the
SBD and an unstable 44-kDa N-terminal fragment containing
the NBD of GRP78 (37). Based on studies of immunoglobulin
(Ig) synthesis, it is known that the conformation of the SubAB-
cleaved GRP78 SBD changes in absence of its regulatory NBD,
and this induces locked-in association of the SBD with newly
synthesized Ig light chains (38). Figure 4C shows co-purification
of full-length endogenous GRP78 and 28-kDa SubAB-cleaved
GRP78 SBD bands with IL-22BPi1, IL-22BPi2, IL-2EX4 but not
IL-22BPi3 demonstrating that any of these interactions occur
with the SBD. Next, we co-transfected the three IL-22BP isoforms
with wild-type (wt) GRP78 or a mutant form of GRP78, in which
substitution of Thr-37 with Gly (T37G) inhibits ATPase activity
and blocks ATP-mediated release of cargo from GRP78 (39). Wt
but not GRP78T37G significantly increased secreted levels of IL-
22BPi1 and IL-22BPi2, while it did not affect secretion of IL-
22BPi3 (Figure 4D). This was mirrored by a tendency toward
increased intracellular levels of IL-22BP isoforms in the presence
of wtGRP78 (Supplementary Figure 5). Thus, the binding of
IL-22BPi1 and IL-22BPi2 to the SBD of GRP78 as well as
their enhanced secretion upon overexpression with wt but not
ATPase-deficient GRP78 suggests that both isoforms are natural
client proteins of GRP78.
IL-22BPi1 and IL-22BPi2 Interact With the
C-Terminal Half (Amino Acids 455-577) of
the Middle Domain of GRP94
As shown above, both IL-22BPi1 and IL-22BPi2 interact with
GRP94. Like GRP78, GRP94 is an ER luminal chaperone,
but unlike GRP78, it has a highly selective client base of
proteins, including specific Toll-like receptors and integrins,
which apart from exhibiting disulfide-bonds share no further
apparent structural features (40, 41). The amount of GRP94
co-IPed via anti-FLAG purification of IL-22BP isoforms from
HEK293 cells transfected with identical quantities of cytokine
vectors was relatively higher for IL-2EX4 than for IL-22BPi1;
GRP94 was borderline detectable in IL-22BPi2 IP (Figure 5A,
left panel). Upon reverse IP using S-tagged GRP94, IL-22BPi1
but not IL-22BPi2 nor BPi3 were found in complex with GRP94.
We were unable to IP S-GRP94 from cells co-transfected with
IL-2EX4 (Figure 5A, right panel). To identify the region(s) in
GRP94 responsible for binding to IL-22BPi1 or IL-22BPi2, we
probed interaction of both isoforms with a series of GRP94
truncation and deletion mutants. This selection of constructs was
based on well-defined GRP94 regions (40) that constitute the
modular fold of GRP94, and was previously used to investigate
the interaction site of GRP94 with OS-9 (42) (Figure 5B). IL-
22BPi1 or IL-22BPi2 were purified from cell lysates by means
of their myc-tag. Although all GRP94 constructs contained both
N-terminal FLAG-tag and C-terminal native KDEL sequences,
their individual detectability in western blot varied according to
the antibody used; mouse anti-FLAG Ab detected the GRP94
middle domain (MD) mutant better than did rabbit anti-
FLAG Ab, and mouse anti-KDEL Ab was only successful in
detecting the GRP94 C-terminal domain (CTD) and1A-GRP94
mutants (Figure 5C). CTD and N-terminal domain (NTD)
GRP94 mutants were not found in complex with either isoform
while the MD-GRP94 and 1A-GRP94 MD variants interacted
strongly with IL-22BPi1 and IL-22BPi2 (Figure 5C). Thus, while
the middle subdomain of GRP94 shared by MD- and 1A-
GRP94 (amino acids 455-577) emerges as critical region for
binding both IL-22BPi1 and IL-22BPi2, this client-binding site
differs from that used by the ERAD component OS-9 [i.e.,
amino acids 356–456 of the GRP94 MD (42)] or by GRP94
client proteins such as TLRs and integrins [i.e., amino acids
635–656 of the GRP94 CTD; (41)]. Co-expression of either
GRP94 MD or 1A mutants with IL-22BPi1 or BPi2 isoforms
significantly decreased their secretion, suggesting that interaction
of these IL-22BP isoforms with these GRP94 mutants sequesters
them from the productive folding/secretory pathway (Figure 5C,
bottom graphs; Supplementary Figure 6). Truncated regions
absent in MD and 1A-GRP94 seem thus to be responsible for
a proper GRP94 – IL-22BP interaction cycle. While the GRP94
NTD mutant did not affect secretion, the GRP94 CTD mutant
appeared to decrease secretion of IL-22BPi1 but not that of IL-
22BPi2, and this possibly reflects additional weak interactions of
IL-22BPi1 with this domain that did not survive the IP procedure.
Co-expression of GFP-tagged wtGRP94 as well as the ATPase-
negative mutant GRP94E82A (43) with IL-22BP isoforms revealed
pronounced co-localization of either GRP94 form with IL-
22BP1 and IL-2EX4 as well as with the reticular portion of IL-
22BPi2 located outside the Golgi apparatus (see also Figure 2B),
but not with IL-22BPi3 (Figure 6). Furthermore, compared to
wtGRP94, GRP94E82A significantly reduced secretion levels of IL-
22BPi1 and IL-22BPi2, but not that of IL-22BPi3. Together, these
experiments provide evidence that GRP94 interacts with both
the former isoforms, and that the secretion of both isoforms is
proportional to intact GRP94 activity.
IL22RA2 Alternatively Spliced Exon-Coded
Sequence Confers Ability to Induce the
UPR Program
This data provides evidence for IL-22BPi1 being an IL-
22 non-binding protein with stronger intrinsic propensity to
misfold than IL-22BPi2. Rather than changing specificity of
intracellular protein interactions based on interactome analysis,
the alternatively spliced exon-encoded sequence appears to
compromise folding and secretion of its recipient protein. Thus,
both IL-22BPi2 and IL-22BPi1 are client proteins of, and interact
with identical domains of, GRP78 and GRP94, but IL-22BPi1
binds more strongly to each of these than IL-22BPi2, is less
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FIGURE 5 | Both IL-22BPi1 and IL-22BPi2 interact with the middle domain of GRP94. (A) HEK293 cells were transiently co-transfected with the indicated expression
plasmids, 24 h later cell lysates were immunoprecipitated with FLAG resin to IP IL-22BP isoforms or IL-2EX4, or with S-tag agarose to IP GRP94.
(Co-)immunoprecipitated proteins (IP) were immunoblotted for GRP94 and FLAG. (B) A schematic diagram of full-length (WT) and structural mutants of GRP94 used.
(C) (Western blot images) HEK293 cells were transiently co-transfected with the indicated expression plasmids, 24 h later cell lysates (CL) were co-immunoprecipitated
with Myc agarose. Membranes with CL and IP proteins were sequentially exposed for detection by KDEL and mouse (Ms) or rabbit (Rb) FLAG Abs, or vice versa.
MD-GRP94 or 1A-GRP94 co-immunoprecipitated with IL-22BPi1 or IL-22BPi2 are indicated with black arrows. (Lower) Expression vectors for IL-22BP isoform-1
and−2 were individually transfected into HEK293 cells together with either GRP94 wild-type (WT) or GRP94 mutant vectors (CTD, MD, NTD, or deltaA) or empty
vector (EV). Twenty-four hour after transfection, secreted IL-22BP was quantified by ELISA, analyzed by paired t-test on original data and represented as fold change
relative to EV condition (mean ± SEM; n = 3; *p < 0.05 by paired t-test, original paired data are represented in Supplementary Figure 6).
efficiently secreted, accumulates intracellularly, and is apparently
confined to the luminal ER seen via immunofluorescence
co-localization with GRP94 and ERp72 coupled to less protein
accumulation in the Golgi apparatus than that seen for IL-
22BPi2 and BPi3. We tested whether expression of IL-22BPi1
activates the unfolded protein response (UPR), a resolutive
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FIGURE 6 | GRP94 ATPase activity is important for IL-22BPi1 and IL-22BPi2 secretion. GRP94 co-localizes with IL-22BPi1 and IL-22BPi2 but not IL-22BPi3. (Left)
Confocal microscopy of HEK293 cells co-transfected with IL-22BP isoforms with the indicated GFP-GRP94 fusion constructs (depicted lower right); IL-22BP was
stained using an anti-IL-22BP antibody (red, IL-22BP Ab 4), IL-2EX4 was stained with mouse anti-FLAG Ab, and the nucleus was stained using DAPI (blue). Secreted
IL-22BP was measured by ELISA in the conditioned media (CM) of HEK293 cells transfected with individual expression vectors for IL-22BP isoforms together with the
indicated GRP94 vectors (upper right) (mean ± SEM; n = 4; **p < 0.01 by unpaired t-test).
transcriptional program to maintain ER homeostasis (44), that
is activated in response to accumulation of misfolded proteins
in the ER. Figure 7A shows that transfection of HEK293 cells
with IL-22BPi1 or IL-2EX4 induces expression of typical UPR
genes including GRP78, GRP94, CHOP, and HERP peaking at
around 36 h after transfection. In contrast, IL-22BPi2, BPi3, or
IL-2 had much less or no effect on induction of these UPR
genes.
Moreover, analysis of cell lysates in western blot revealed that
appearance of IL-22BPi1 or IL-2EX4 at 24 h after transfection
is associated with increased protein levels of GRP94 and
GRP78 (Figure 7B). No such effects were seen with IL-
22BPi2, IL-22BPi3, or IL-2. Activation of the UPR was
confirmed by enhanced splicing of XBP1 in cells expressing
IL-22BPi1 or IL-2EX4 (Figure 7C). Given the observation that
ectopic GRP78 enhanced secretion of both IL-22BPi2 and
BPi1 (see Figure 4D), we analyzed whether co-transfection
of IL-22BPi2 with IL-22BPi1 may, similarly, enhance IL-
22BP secretion secondary to UPR induction of GRP78 by IL-
22BPi1. Figure 7D shows that at a BPi1:BPi2 1:1 transfection
ratio, reduced secretion of IL-22BP measured in ELISA was
seen, while at smaller ratios approaching those seen in
natural producer cells (see Figure 1) at best a non-significant
trend toward enhanced secretion of immunoreactive protein
was observed (same effect was observed when IL-22BPi2
was co-transfected with IL-2 or IL-2EX4 rather than IL-
22BPi1, Supplementary Figure 7). We assayed if UPR activation
compromised cell viability in this experiment, but this was not
the case (Figure 7E).
Expression of IL-22BP Affects GRP78
Levels in Immature moDCs
We asked whether the link between IL-22BPi1 and GRP78
induction is active in natural producer cells. If so, reduction of
IL-22BP expression levels by silencing should decrease GRP78
levels in monocyte-derived DC cells. Prior to this experiment, we
had noted that a proportion of monocytes purified from
PBMCs without prior cultivation, around 10%, stained
intensely positively for IL-22BP upon immunofluorescence
microscopy, suggesting ongoing IL-22BP synthesis in a subset
of unprimed and unstimulated monocytes of healthy donors
(Figure 8A). Since three types of monocytes in the blood are
commonly distinguished on the basis of CD14 and CD16 surface
expression (45) (i.e., classical, CD14++ CD16−; non-classical,
CD14+CD16++; intermediate, CD14++CD16+), we analyzed
whether differential expression of IL-22BP in these types may
explain the observed microscopic discrepancies. Analysis of
IL22RA2 and cytokine expression in purified CD16−CD14+
and CD16+ monocyte subpopulations, and their corresponding
immature or IFN-γ/LPS-matured dendritic cells showed higher
expression of IL22RA2 in CD16+ monocytes and CD16+
monocyte-derived immature DCs compared to the respective
CD16−CD14+ subsets (Supplementary Data 1). Classical,
intermediate and non-classical monocytes were subsequently
separated by FACS, and IL22RA2 expression was analyzed in
each subtype (Gating strategy in Supplementary Figure 1).
Though all three monocyte types expressed similar ratios
of IL22RA2v1 vs. IL22RA2v2 mRNA, Figure 8B shows that
intermediate CD14++CD16+ monocytes produced the highest
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FIGURE 7 | IL-22BPi1 and IL-2EX4 induce unfolded protein response (UPR) genes. HEK293 cells were transiently transfected with IL-22BPi1, IL-22BPi2, IL-22BPi3,
IL-2, IL-2EX4 or empty vector (EV) as control. Cells were collected at the indicated hours after transfection. (A) Expression of different genes related to ER function or
UPR were analyzed by RT-qPCR. Each gene expression value is represented as fold change relative to the same time-point expression value of the EV condition and
relative to the housekeeping gene GAPDH. Mean ± SEM of three independent experiments. All primers are listed in Supplementary Table 2. (B) GRP78 and GRP94
(Continued)
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FIGURE 7 | protein levels correlate with mRNA levels observed in (A). Cell lysates (CL) were immunoblotted for FLAG, GRP94, KDEL and tubulin as loading control.
(C) IL-22BPi1 and IL-2EX4 cause XPB1 splicing. XBP1 splicing was detected with conventional PCR for the indicated conditions and times. Un-spliced and spliced
XBP1 are indicated as XBP1-u or XBP-1s respectively. (D) IL-22BPi2 secretion was not increased when co-expressed with different ratios of IL-22BPi1. HEK293 cells
were co-expressed with different ratios of EV:IL-22BPi1:IL-22BPi2 expression plasmids. 48 h later, secreted IL-22BP in conditioned media (CM) was quantified by
ELISA (mean ± SEM; n = 3). (E) Cell viability measured with alamarBlue was not compromised by any of the conditions in two different cell lines. Reduction of
alamarBlue was measured after 48 h of transfection and assayed for the indicated times and cell lines. Values are represented as percentage of reduction in each
condition relative to EV (mean ± SEM; n = 3).
overall levels of IL22RA2 and isoform-specific IL22RA2v1 and
v2 mRNAs. This was validated on the protein level by direct
counting of IL-22BP+ cells in immunofluorescence microscopy
(Figure 8B, lower panel). Next, we differentiated the three
monocyte types into immature moDCs. At day 6, the non-
classical type showed extensive cell death in line with a previous
report and was excluded from further analysis (46). However,
in contrast to the primary uncultivated monocytes, classical
and intermediate moDCs showed higher and reciprocally
similar levels of IL22RA2v1 and v2 mRNA (Figure 8C). In
silencing experiments, therefore, moDCs derived from CD14+
unfractionated monocytes were used. Using a polymer-based
transfection reagent (i.e., viromer), we achieved over 85%
reduction of IL22RA2 mRNA levels using 100 nM siRNA,
with both IL22RA2v1 and v2 reduced to a similar extent
(Figures 8D,E). Following comparison of various silencing
procedures, we found that silencing on day 0 of the cultivation
period, repeated on day 3, followed by harvest on day 6, resulted
in the most pronounced reduction of both IL22RA2 mRNA and
intracellular IL-22BP protein measured by ELISA (condition B in
Figure 8F). Silencing done on day 1 or 2 was much less effective
condition C and D in Figure 8F), while a unique silencing on
day 0 was less effective in reducing IL-22BP protein (condition A
in Figure 8F). In none of these conditions did IL22RA2 silencing
affect cell viability measured by alamarBlue. Condition B was
applied to moDCs from unrelated healthy donors, co-cultivated
or not with AM580. Measured by qPCR, IL22RA2 and GRP78
mRNA levels were significantly reduced in both conditions,
while ERP44, a gene less strongly affected by IL-22BPi1-induced
UPR in HEK293 cells [(47); see also Figure 7A], was reduced to a
lesser extent and only significantly so in AM580-treated moDCs
(Figure 8G). Thus, IL22RA2 expression level in immature
moDCs influences GRP78 expression level.
DISCUSSION
IL-22BPi1 differs from IL-22BPi2, a secreted high-affinity IL-22
antagonist, by the insertion of a 32-amino acid sequence coded
for by an alternatively spliced exon. This insertion occurs at
position 67 of IL-22BPi2 (231 amino acids) and does not disrupt
the reading frame as a consequence of which the intact primary
sequence of IL-22BPi2 is in its entirety included in IL-22BPi. The
biological function of IL22BPi1 is not known. Here, we show
that IL-22BPi1 displays hallmarks of a poorly secreted, misfolded
protein incapable of binding IL-22 in biological or co-folding
assays. IL-22BPi1, but not IL-22BPi2 or BPi3, induced a UPR
response resulting in higher GRP78 and GRP94 protein levels.
Silencing of IL-22BP in immature CD14+ monocyte-derived
DCs reduced GRP78 expression. This study describes a novel
intracellular function of IL-22BPi1 unrelated to neutralization of
IL-22.
In immature moDCs, the human IL22RA2 gene co-expresses
mRNAs for three protein isoforms that share the same signal
peptide and should therefore be secreted. In line with earlier
observations, treatment of moDCs with retinoic acid receptor
agonist AM580 increases, while maturation with IFN-γ and
LPS strongly suppresses IL22RA2 mRNA levels (5). Though
discernible by ELISA, IL-22BP secreted by moDCs was poorly
detected in CM or acetone precipitates via western blot. Thus,
to determine the biochemical characteristics and secretory
potential of each isoform we used HEK293 cells transfected with
individual expression vectors for IL-22BPi1, IL-22BPi2 or IL-
22BPi3. Similar to Lim and colleagues (12), we were unable to
detect IL-22BPi1 in concentrated culture medium of transfected
cells by western blot, though we could discern small amounts
of secreted protein by ELISA. Subcloning of the alternatively
spliced exon from IL-22BPi1 into IL-22BPi3 arrested the latter’s
secretion (12). In this work, insertion of this exon into the reading
frame of IL-2 (IL-2EX4), an abundantly secreted cytokine, was
sufficient to block its secretion. IL-22BPi2 and IL-22BPi3, but
not IL-22BPi1, were mainly visible as intensely staining deposits
co-localizing with a trans-Golgi protein marker. The diffuse
perinuclear staining pattern of IL-22BPi1, in contrast, resembled
that of the luminal ER protein ERP72, suggesting that the extra
sequence acts as a powerful ER retention signal limiting transit
toward the Golgi apparatus. We set out to determine the factors
that cause intracellular retention of IL-22BPi1. GRP78, a crucial
luminal ER chaperone involved in translocation, folding and
retrograde transport of newly synthesized proteins via direct
interaction with the polypeptide backbone (48) was identified in
the interactome analysis of the affinity-tagged IL-22BP isoforms
purified from total cell lysates as main interacting partner of IL-
22BPi1, IL-22BP2, and IL-2EX4. These three proteins, but not
IL-22BPi3, were found to interact with the SBD of GRP78. Co-
transfection with wtGRP78, but not the ATPase-negative T37G
GRP78mutant (39) significantly increased secretion of IL-22BPi1
and BPi2, but not that of BPi3, as measured in ELISA. Thus,
both IL-22BPi1 and IL-22BPi2 appear to behave as bona fide
secretory client proteins of GRP78, and the extra exon sequence
does not appear to change site of interaction with GRP78.
Interactomes of IL-22BPi2 purified from either HEK293 or HeLa
cells reproducibly contained, apart from GRP78, also calnexin,
GRP170 and GRP94, suggesting extensive ER quality control
scrutiny of its folding. These chaperones, as well as ERdj3, were
found to interact with both IL-22BPi2 and IL-22BPi1 in western
blot analysis. The C-terminal half (amino acids 455-577) of the
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FIGURE 8 | Silencing of IL22RA2 in immature moDCs reduces GRP78 expression. (A) CD14+ monocytes were stained with DAPI (blue), trans-GOLGI (red) and
IL-22BP (green, IL-22BP Ab 4). (B) Overall (best coverage, BC) and isoform-specific IL22RA2 expression levels in classical, intermediate and non-classical monocyte
subpopulations (top) from four healthy donors (average ± SEM). Percentages of IL-22BP+ monocytes found in each subpopulation by immunofluorescence
microscopy (bottom) (mean ± SEM; n = 4; *p < 0.05, Kruskal-Wallis test for comparison of differences in IL22RA2 mRNA levels or IL-22BP+ counts in the three
subpopulations). (C) IL22RA2 expression levels in classical and intermediate immature moDCs at day 6 of cultivation. moDCs derived from non-classical monocytes
showed high levels of cell death and had not experienced any changes in the shape of the cells. High Ct values of HK gene HPRT1 in qPCR compromised correct
interpretation of IL22RA2 levels in this subgroup, which was therefore excluded from the graph. (D) Fold change relative to non-targeting siRNA control of IL22RA2
(Continued)
Frontiers in Immunology | www.frontiersin.org 17 December 2018 | Volume 9 | Article 2934
Gómez-Fernández et al. Characterization of Human IL-22BP Isoforms
FIGURE 8 | expression in CD14+ monocyte.-derived immature DCs on day 5 of cultivation following IL22RA2 silencing with Viromer Green at two concentrations of
siRNA. (E) Silencing as described in (D) was not variant specific and both IL22RA2v1 and v2 were silenced to similar extent. (F) Scheme comparing efficiencies of four
distinct silencing strategies on suppression of IL22RA2 mRNA (qPCR) and intracellular IL-22BP (ELISA) in immature CD14+ moDCs using 100 nM IL22RA2 siRNA or
non-targeting siRNA in combination with Viromer Green. S, silencing, H, harvest. Bar diagrams represent fold change relative to non-targeting siRNA. (G) Effect of
IL22RA2 silencing on GRP78 and ERp44 mRNA levels in CD14+ monocyte-derived immature DCs from healthy donors using silencing strategy B in (F). CD14+
monocytes were cultivated in DM medium in the absence or presence of AM580 starting on day 0 up to the day of harvest. Average of fold change (±SEM) relative to
non-silencing control over 6 (control) and 5 (AM580) independent measurements relative to the housekeeping gene HPRT1. *p < 0.03 by Wilcoxon test.
middle domain of GRP94 was identified as critical client binding
region of both IL-22BPi1 and BPi2. This region differs from that
identified for the GRP94 clients OS-9 or TLRs and integrins (41,
42), but the implications are as yet difficult to interpret given the
scarcity of information on the mechanisms defining interaction
of client proteins with GRP94. The ATPase-negative GRP94
MD and 1A mutants that show strong interaction with both
isoforms, also reduced their secretion, indicative for competition
with a productive “pro-secretion” role of GRP94 in IL-22BPi1
or IL-22BPi2 folding dependent on functionally intact GRP94.
IL-22BPi1 and IL-2EX4 showed virtually perfect co-localization
with GRP94 identifying this chaperone as crucially associated
with their arrest of transit to Golgi. Calnexin is part of the
ER quality control system that acts to retain unfolded N-linked
glycoproteins (49), compatible with mono-glucosylation of the
high-mannose type N-glycans we identified on intracellular IL-
22BP isoforms. GRP170, an HSP70-type chaperone, and ERdj3 a
DnaJ-family GRP78 co-factor, recognize distinct sets of peptide
sequences in unfolded proteins; interestingly, while GRP78 and
ERdj3 can interact with many diverse client peptide sequences,
GRP170 was shown recently to interact specifically with rarer,
aggregation-prone regions which, if continuously exposed, may
trigger disposal of the protein by ERAD given the toxicity of
protein aggregates to cell survival (50). This potential link to
ERAD is substantiated by the observation that both IL22-BPi1
and IL-22BPi2, but not IL-22BPi3, appear to be partially degraded
by the proteasome.
We investigated whether co-expression of IL-22BP isoforms
with their ligand IL-22 may alleviate the formers degradation
through enhanced secretion via assembly-induced folding. Such
process has been documented in detail for IL-15 that is pre-
assembled in complex with IL-15Rα in the ER/Golgi of DCs.
IL-15Rα acts as a chaperone for unstable IL-15 inhibiting its
degradation through the proteasome (32, 36). A different but
related process takes place in eosinophils, where an intracellular
pool of IL-4Rα enhances secretory trafficking of IL-4 for rapid
mobilization into secretory vesicles prior to secretion (51).
For IL-12 and IL-23, co-expression of the shared β-subunit
(p40) inhibits misfolding of the poorly secreted α-subunits (p35
and p19, respectively) facilitating secretion of the functional
heterodimers (52, 53). In line with these studies, we found
that co-expression of IL-22 enhanced secretory transit of IL-
22BPi2 and IL-22BPi3 resulting in much higher levels of secreted
proteins. This was not seen for IL-22BPi1 of which secretion
levels were unaffected by IL-22 co-expression. We were not able
to detect expression of IL-22 in immature or mature moDCs
by qPCR; thus, whether IL-22 – IL-22BPi2 assembly-induced
folding takes place in any other natural producer cell types such
as CD4+ T lymphocytes (10) remains to be determined. However,
together with bioactivity measurements, which showed that IL-
22BPi2 but not IL-22BPi1 when used at similar concentrations,
inhibited STAT3 phosphorylation by IL-22, it appears that IL-
22BPi1 is naturally incapable of interacting with IL-22. This is
in accordance with the location of residues critical for binding
of IL-22BPi2 to IL-22, especially Lys65 and Tyr67, close to the
position of insertion of the alternatively spliced exon in IL-
22BPi1 (15, 54). Dumoutier et al. (55) demonstrated that of
the IL-10-type homologs including IL-19, IL-20, and IL-24,
only IL-22 was able to bind to IL-22BPi2. These observations
render the potential for any residual interaction between IL-10-
type cytokines and IL-22BPi1 that may “rescue” its misfolding
highly unlikely. We tested the capacity of IL-22BP isoforms
to activate ER stress signaling via induction of UPR through
accumulation of misfolded protein (56). IL-22BPi1 strongly
upregulated expression of UPR genes resulting in increased
GRP78 and GRP94 protein levels, suggesting that under these
experimental conditions ERAD alone is insufficient to restore ER
folding capacity (57). In contrast, IL-22BPi2 did not augment
GRP78 and GRP94 protein levels indicating that its more
balanced export from the ER through either secretion or ERAD
may eliminate the need for UPR induction. Mirroring the
findings in recombinant cells, silencing of IL22RA2 expression
in immature CD14+ monocyte-derived DCs coincided with
reduced GRP78 expression.
The failure of IL-22BPi1 to fold may be partially due
to the general tendency of alternatively spliced exons to
encode intrinsically disordered protein segments (58). In fact,
exonization processes may act as mechanisms to add disordered
regions to proteins, and many of these play a role in protein-
protein interactions (59). The alternatively spliced exon of
IL22RA2v1 evolved from a retrotransposon of the mammalian
apparent Long Terminal Repeat family (MaLR) specific to the
great ape lineage that became active consequential to a single
mutation in the proto-splice site (60). Computational structure
prediction of the three mature IL-22BP isoforms shows that
the only region with high intrinsic disorder profile is that
coded for by this exon (Supplementary Figure 8). Moreover, the
sequence and conformation of IL-22BPi2 have phenotypically
evolved for high-affinity binding to and neutralization of IL-
22. The presence of the extra exon in IL-22BPi1 breaks this
selection pressure. We cannot exclude the possibility that
specific beneficial interactions with IL-22BPi1 occur with as
yet undetermined partners within natural producer cells or in
the extracellular milieu. Our work suggests that one benefit of
co-expression of IL-22BPi1 with IL-22BPi2 may reside in its
ability through UPR induction to augment GRP78 and GRP94
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levels. Since both these chaperones are instrumental in the
folding of IL-22BPi2, enhanced secretion levels of IL-22BPi2 by
moDCs could thus constitute a positive selectable trait. This will
need to be investigated by abolishment of isoform-1 expression
in moDCs through genome modification techniques such as
CRISPR. Finally, pending further investigation, constitutively
higher levels of ER chaperones may prepare the ER of immature
moDCs for enhanced processing potential of secretory and
membrane proteins including MHC receptors, integrins and
cytokines which are massively expressed immediately upon
receipt of TLR ligands or other maturation triggers (61).
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